Aptorum APM Stock
Aptorum Price Chart
Aptorum APM Financial and Trading Overview
| Aptorum stock price | 0.83 USD |
| Previous Close | 0.83 USD |
| Open | 0.86 USD |
| Bid | 0.61 USD x 200 |
| Ask | 1.07 USD x 200 |
| Day's Range | 0.82 - 0.89 USD |
| 52 Week Range | 0.65 - 4.47 USD |
| Volume | 75.54K USD |
| Avg. Volume | 140.75K USD |
| Market Cap | 6.99M USD |
| Beta (5Y Monthly) | 0.116 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.19 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
APM Valuation Measures
| Enterprise Value | -2391603 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.2087325 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.30239606 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.531 |
Trading Information
Aptorum Stock Price History
| Beta (5Y Monthly) | 0.116 |
| 52-Week Change | -11.54% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 4.47 USD |
| 52 Week Low | 0.65 USD |
| 50-Day Moving Average | 0.9 USD |
| 200-Day Moving Average | 1.17 USD |
APM Share Statistics
| Avg. Volume (3 month) | 140.75K USD |
| Avg. Daily Volume (10-Days) | 434.08K USD |
| Shares Outstanding | 6.35M |
| Float | 5.36M |
| Short Ratio | 0.07 |
| % Held by Insiders | 16.40% |
| % Held by Institutions | 2.46% |
| Shares Short | 2.48K |
| Short % of Float | 0.040% |
| Short % of Shares Outstanding | 0.029% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -6.52% |
| Return on Equity (ttm) | -10.78% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -1562482 USD |
| Net Income Avi to Common (ttm) | -1363270 USD |
| Diluted EPS (ttm) | -0.19 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.45M USD |
| Total Cash Per Share (mrq) | 0.42 USD |
| Total Debt (mrq) | 3.44M USD |
| Total Debt/Equity (mrq) | 25.05 USD |
| Current Ratio (mrq) | 0.782 |
| Book Value Per Share (mrq) | 2.838 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1836546 USD |
| Levered Free Cash Flow (ttm) | -1097453 USD |
Profile of Aptorum
| Country | United States |
| State | N/A |
| City | London |
| Address | 17 Hanover Square |
| ZIP | W1S 1BN |
| Phone | 44 20 8092 9299 |
| Website | https://www.aptorumgroup.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1 |
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Q&A For Aptorum Stock
What is a current APM stock price?
Aptorum APM stock price today per share is 0.83 USD.
How to purchase Aptorum stock?
You can buy APM shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aptorum?
The stock symbol or ticker of Aptorum is APM.
Which industry does the Aptorum company belong to?
The Aptorum industry is Biotechnology.
How many shares does Aptorum have in circulation?
The max supply of Aptorum shares is 8.14M.
What is Aptorum Price to Earnings Ratio (PE Ratio)?
Aptorum PE Ratio is now.
What was Aptorum earnings per share over the trailing 12 months (TTM)?
Aptorum EPS is -0.19 USD over the trailing 12 months.
Which sector does the Aptorum company belong to?
The Aptorum sector is Healthcare.
Aptorum APM included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2310.38 USD — |
-1.07
|
— — | 2287.99 USD — | 2333.46 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}